
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is a leading provider of integrated, temperature-controlled supply chain solutions for the life sciences industry. The company has a strong focus on supporting the cell and gene therapy market, which is a fast-growing and highly promising segment. With its comprehensive portfolio of services and products, strong revenue visibility, and growing customer base, CryoPort is well-positioned to capitalize on the growth opportunities in the cell and gene therapy market. Moreover, the company's strong financial performance and margin expansion potential are promising signs for future profitability.
Bears say
CryoPort is expected to have strong commercial revenues, but their guidance is based strictly on therapies currently approved, leaving room for potential revenue declines. Additionally, there are risks associated with clinical trial progression, competition in the market, and macro pressures on their MVE business. There is potential for upside if there are more approvals for cell and gene therapies distributed through CryoPort's logistics platform, but there is also a risk of slower approvals and increased competition in the cold-chain logistics market.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares